12:00 AM
Sep 15, 2008
 |  BC Week In Review  |  Company News  |  Deals

BioSpecifics deal

BioSpecifics made a one-time cash payment to reduce the royalties it would owe to an undisclosed third-party for Xiaflex (formerly AA4500) to treat Peyronie's disease. The amount...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >